Filtered By:
Condition: Diabetes Mellitus
Drug: Empagliflozin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 40 results found since Jan 2013.

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Clinical Sciences
Conclusions—In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01131676.
Source: Stroke - April 24, 2017 Category: Neurology Authors: Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, David Fitchett, Sven Kohler, Michaela Mattheus, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen, Gregory W. Albers, Hans Christoph Diener Tags: Cardiovascular Disease, Diabetes, Type 2, Cerebrovascular Disease/Stroke, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality. Current therapeutic strategies have not provided constant beneficial cardiovascular-related results. Sodium–glucose co-transporters 2 (SGLT-2) inhibitors have emerged as a novel antidiabetic class of drugs that exert favourable results in a variety of other cardiovascular risk factors too, such as increased blood pressure and body weight. The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study was the first trial that evaluated cardiovascular outcomes in patients with diabetes with the us...
Source: Journal of Neurology, Neurosurgery and Psychiatry - February 16, 2017 Category: Neurosurgery Authors: Imprialos, K. P., Boutari, C., Stavropoulos, K., Doumas, M., Karagiannis, A. I. Tags: Stroke, Hypertension Cerebrovascular disease Source Type: research

Sodium-glucose cotransporter 2 inhibitors and ischemic stroke.
CONCLUSION: Despite the multiple pleiotropic effects of SGLT-2 inhibitors, these agents do not appear to affect stroke risk. Ongoing large trials with longer follow-up will evaluate whether the pleiotropic effects of this class will translate into benefits in ischemic stroke prevention. PMID: 29412119 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Letter by Tampaki et al Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk” Letter to the Editor
Source: Stroke - August 28, 2017 Category: Neurology Authors: Ekaterini Christina Tampaki, Athanasios Tampakis, Lorenz Gurke Tags: Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Response by Zinman et al to Letter Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk” Letter to the Editor
Source: Stroke - August 28, 2017 Category: Neurology Authors: Bernard Zinman, Silvio E. Inzucchi, Hans Christoph Diener Tags: Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Incidence of adverse cardiovascular events in type  2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata Tags: Original Article Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

The EMPA-REG Study: What has it told us? A Diabetologist’s Perspective
EMPA-REG (1) is the first study to conclusively demonstrate that a medication developed to reduce glycemia (2) in patients with type 2 diabetes mellitus (T2DM) decreases cardiovascular events. In 7020 T2DM patients with established cardiovascular (CV) disease, empagliflozin (pooled 10 and 25 mg/day doses) significantly reduced the primary MACE outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% compared to placebo (HR = 0.86, 95% CI = 0.74-0.99, P=0.04 for superiority). It is noteworthy that a striking disconnect was observed between the three MACE components; (i) for nonfatal MI, the HR (=0.87) decreased s...
Source: Journal of Diabetes and Its Complications - October 21, 2015 Category: Endocrinology Authors: Ralph A. DeFronzo Source Type: research

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research

Cardiovascular safety outcomes of new antidiabetic therapies.
CONCLUSION: A review of cardiovascular safety outcomes for new antidiabetic agents found that saxagliptin and alogliptin were associated with an increase in hospitalization for HF. The data for empagliflozin, liraglutide, and semaglutide showed a reduction in cardiovascular events and death or a neutral effect on cardiovascular endpoints. PMID: 28483748 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - May 8, 2017 Category: Drugs & Pharmacology Authors: LeBras MH, Barry AR, Koshman SL Tags: Am J Health Syst Pharm Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials
ConclusionsIn patients with T2DM, compared with pure SGLT2 inhibitors, combined SGLT1/2 inhibitors demonstrated a lower risk of myocardial infarction and of stroke, but were associated with a higher risk of diarrhea and severe hypoglycemia.
Source: American Journal of Cardiovascular Drugs - March 22, 2022 Category: Cardiology Source Type: research